Rufinamide for the treatment of Lennox-Gastaut syndrome

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 5, 2011, Pages 801-806

  Besag, Frank M C ^a  

^a South Essex Partnership Foundation NHS Trust ^*  (United Kingdom)

Author keywords

efficacy; Lennox Gastaut; pivotal trial; rufinamide; safety; tolerability

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; E 2080; FELBAMATE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; RUFINAMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN;

ANOREXIA; ANTICONVULSANT THERAPY; ARTICLE; BEHAVIOR DISORDER; BENIGN CHILDHOOD EPILEPSY; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIPLOPIA; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTROL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EXHAUSTION; FATIGUE; FEVER; FOCAL EPILEPSY; HEADACHE; HUMAN; LEARNING DISORDER; LENNOX GASTAUT SYNDROME; MAXIMUM PLASMA CONCENTRATION; MENTAL DEFICIENCY; MONOTHERAPY; NAUSEA; NYSTAGMUS; PLASMA CLEARANCE; POSTMARKETING SURVEILLANCE; QUALITY ADJUSTED LIFE YEAR; RASH; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SLEEP DISORDER; SOMNOLENCE; SPIKE WAVE; TONIC CLONIC SEIZURE; TREMOR; VISUAL DISORDER; VOMITING;

BIOLOGICAL AVAILABILITY; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; HALF-LIFE; HUMANS; MENTAL RETARDATION; PLACEBOS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPASMS, INFANTILE; TRIAZOLES;

EID: 79952600376     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.560836     Document Type: Article

References (28)

1. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology [Review]. Lancet Neurol 2009;8:82-93
2. Dulac O, Engel J. Lennox-Gastaut Syndrome. 2003. Available from: http://www.ilae-epilepsy.org/visitors/centre/ctf/lennox-gastaut.html [Last accessed 11 December 2010]
3. Kieffer-Renaux V, Kaminska A, Dulac O. Cognitive deterioration in Lennox-Gastaut and Doose epilepsy. In: Jambaque I, Lassonde M, Dulac O, editors, Neuropsychology of childhood epilepsy. Kluwer Academic/Plenum Publishers, New York; 2001. p. 185-90
4. Deekollu D, Besag FM, Aylett SE. Seizure-related injuries in a group of young people with epilepsy wearing protective helmets: incidence, types and circumstances. Seizure 2005;14:347-53 (Pubitemid 40916319)
5. Besag FM. Behavioural effects of the newer antiepileptic drugs: an update [Review]. Expert Opin Drug Saf 2004;3:1-8 (Pubitemid 38765182)
6. Besag FM. Behavioral aspects of pediatric epilepsy syndromes [Review]. Epilepsy Behav 2004;5(Suppl 1):S3-13
7. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997;337:1807-12 (Pubitemid 28006785)
8. Published erratum appears in N Engl J Med 1998;339:851-2
9. Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL study group. Neurology 1999;52:1882-7 (Pubitemid 29260904)
10. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The felbamate study group in lennox-gastaut syndrome. N Engl J Med 1993;328:29-33
11. Schmidt D, Kramer G. The new anticonvulsant drugs. Implications for avoidance ofadverse effects [Review]. Drug Saf 1994;11:422-31
12. Felbamate linked to aplastic anemia; warning issued on drug's use. Am J Hosp Pharm 1994;51:2324
13. You SJ, Kang HC, Ko TS, et al. Comparison of corpus callosotomy and vagus nerve stimulation in children with Lennox-Gastaut syndrome. Brain Dev 2008;30:195-9 (Pubitemid 351265386)
14. Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia 2001;42:1148-52 (Pubitemid 32947934)
15. Freeman JM. The ketogenic diet: additional information from a crossover study. J Child Neurol 2009;24:509-12
16. Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009;50:1158-66
17. Sheth RD, Goulden KJ, Ronen GM. Aggression in children treated with clobazam for epilepsy. Clinical Neuropharmacology 1994;17(4):332-7 (Pubitemid 24239383)
18. Sheth RD, Goulden KJ, Ronen GM. Aggression in children treated with clobazam for epilepsy. Clin Neuropharmacol 1994;17:332-7 (Pubitemid 24239383)
19. Inovelon Summary ofProduct Characteristics. 2009 Dec 15. Available from: http://www.medicines.org.uk/emc/medicine/20165/SPC/[Last accessed 12 December 2010]
20. Eisai, Inc. Banzel (rufinamide) prescribing information. 2011. Available from: http://www.eisai. com/package-inserts/Banzel-PI pdf [Last accessed 29 January 2011]
21. Elger CE, Stefan H, Mann A, et al. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010;88:255-63
22. Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009;14:491-5
23. Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010;17:546-8
24. Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70:1950-8
25. Vendrame M, Loddenkemper T, Gooty VD, et al. Experience with rufinamide in a pediatric population: a single center's experience. Pediatric Neurol 2010;43:155-8
26. Olsen HE, Loddenkemper T, Vendrame M, et al. Rufinamide for the treatment of epileptic spasms. Epilepsy Behav 2011;1-5, doi:10.1016/j. yebeh.2010.11.023
27. Gallop K, Wild D, Nixon A, et al. Impact of Lennox-Gastaut Syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review [Review]. Seizure 2009;18:554-8
28. Verdian L, Yi Y. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom. Seizure 2010;19:1-11